// App-Quantinova.ai

4825 : A rationale for treatment of colorectal cancer with mitomycin C and crizotinib

Researchers

Presenter

  • Avital Lev

Principal Investigators

  • Elena Shagisultanova

  • Safoora Deihimi

  • David T. Dicker

  • Joanne Xui

  • Wafik S. El-Deiry

Medical Centers

  • Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA.

  • Division of Medical Oncology, Anschutz Cancer Center, University of Colorado, Denver, CO

  • Caris Life Sciences, Phoenix, AZ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Lynch syndrome

  • Solid malignancies

Biomarkers

  • Anaplastic lymphoma Kinase

  • Cluster of Differentiation 206

  • Hepatocyte growth factor

  • BRCA mutation

  • Microsatellite instability-high

  • Microsatellite instability

Drug/Treatment

  • Crizotinib

  • mitomycin

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved